Cargando…
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy
Lung cancer is the most common malignancy worldwide and is a focus for developing targeted therapies due to its refractory nature to current treatment. We identified a RNA helicase, DDX3, which is overexpressed in many cancer types including lung cancer and is associated with lower survival in lung...
Autores principales: | Bol, Guus M, Vesuna, Farhad, Xie, Min, Zeng, Jing, Aziz, Khaled, Gandhi, Nishant, Levine, Anne, Irving, Ashley, Korz, Dorian, Tantravedi, Saritha, Heerma van Voss, Marise R, Gabrielson, Kathleen, Bordt, Evan A, Polster, Brian M, Cope, Leslie, van der Groep, Petra, Kondaskar, Atul, Rudek, Michelle A, Hosmane, Ramachandra S, van der Wall, Elsken, van Diest, Paul J, Tran, Phuoc T, Raman, Venu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492822/ https://www.ncbi.nlm.nih.gov/pubmed/25820276 http://dx.doi.org/10.15252/emmm.201404368 |
Ejemplares similares
-
Role of DDX3 in the pathogenesis of inflammatory bowel disease
por: Tantravedi, Saritha, et al.
Publicado: (2017) -
Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer
por: Heerma van Voss, Marise R, et al.
Publicado: (2017) -
Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach
por: Heerma van Voss, Marise R., et al.
Publicado: (2018) -
Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment
por: Heerma van Voss, Marise R., et al.
Publicado: (2017) -
Expression of the RNA Helicase DDX3 and the Hypoxia Response in Breast Cancer
por: Bol, Guus M., et al.
Publicado: (2013)